Jean Borges Bertoldo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean Borges Bertoldo has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Hernán Terenzi
Centro de Biologia Molecular Estrutural, Departamento de Bioquímica, Universidade Federal de Santa Catarina , 88040-970 Florianópolis , SC , Brazil
9 shared publications- Ana Carolina Maisonnave Arisi
Universidade Federal de Santa Catarina
5 shared publications - Gonçalo Bernardes
Yusuf Hamied Department of Chemistry University of Cambridge Cambridge UK
5 shared publications Javier Vernal
Centro de Biologia Molecular Estrutural, Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Campus Trindade, 88040-900, Florianópolis, SC, Brazil
5 shared publicationsFábio Cristiano Angonesi Brod
Departmento de Ciência e Tecnologia de Alimentos, Universidade Federal de Santa Catarina, 88040900 Florianópolis, SC, Brazil
4 shared publicationsStefan Hüttelmaier
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
CanProTarget: A Residue-Resolved Platform for Covalent Target Identification and Drug Discovery in Cancer
Dependency maps nominate transcription factors, RNA-binding proteins and scaffolds without conventional binding sites, while cysteine chemoproteomics has mapped tens of thousands of ligandable sites without reference to disease. Covalent campaigns therefore begin from what is tractable rather than from what a cancer requires. Whether a ligandable cysteine matters requires residue-level functional evidence, and no resource holds all three: combined at the gene level, function measured at one cysteine is credited to a ligand bound at another. We developed CanProTarget to establish where covalent chemistry can realistically begin, returning target–cysteine–ligand hypotheses rather than gene lists. Across twenty adult and pediatric cohorts, 63–75% of gene-level candidates lost support under residue matching. Roughly 80% of ligandable sites were untested rather than assayed non-functional, and the tiers keep them distinct. One untested site nominated IGF2BP3–Cys336–CL174 in neuroblastoma; CL174 engaged IGF2BP3, reduced its mRNA binding and, with depletion, identified BRD3 and H3-3A as IGF2BP3 targets.
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCanProTarget: A Residue-Resolved Platform for Covalent Target Identification and Drug Discovery in Cancer
Dependency maps nominate transcription factors, RNA-binding proteins and scaffolds without conventional binding sites, while cysteine chemoproteomics has mapped tens of thousands of ligandable sites without reference to disease. Covalent campaigns therefore begin from what is tractable rather than from what a cancer requires. Whether a ligandable cysteine matters requires residue-level functional evidence, and no resource holds all three: combined at the gene level, function measured at one cysteine is credited to a ligand bound at another. We developed CanProTarget to establish where covalent chemistry can realistically begin, returning target–cysteine–ligand hypotheses rather than gene lists. Across twenty adult and pediatric cohorts, 63–75% of gene-level candidates lost support under residue matching. Roughly 80% of ligandable sites were untested rather than assayed non-functional, and the tiers keep them distinct. One untested site nominated IGF2BP3–Cys336–CL174 in neuroblastoma; CL174 engaged IGF2BP3, reduced its mRNA binding and, with depletion, identified BRD3 and H3-3A as IGF2BP3 targets.
- Open Access
- 25 September 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Chemoproteomics in covalent cancer drug discovery
- 25 September 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Open AccessChemoproteomics in covalent cancer drug discovery
- 7 April 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (6)
RNA-binding proteins in cancer drug discovery
- 7 April 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (6)
RNA-binding proteins in cancer drug discovery
- Open Access
Protein Modifications: From Chemoselective Probes to Novel Biocatalysts
Chemical reactions can be performed to covalently modify specific residues in proteins. When applied to native enzymes, these chemical modifications can greatly expand the available set of building blocks for the development of biocatalysts. Nucleophilic canonical amino acid sidechains are the most readily accessible targets for such endeavors. A rich history of attempts to design enhanced or novel enzymes, from various protein scaffolds, has paved the way for a rapidly developing field with growing scientific, industrial, and biomedical applications. A major challenge is to devise reactions that are compatible with native proteins and can selectively modify specific residues. Cysteine, lysine, N-terminus, and carboxylate residues comprise the most widespread naturally occurring targets for enzyme modifications. In this review, chemical methods for selective modification of enzymes will be discussed, alongside with examples of reported applications. We aim to highlight the potential of such strategies to enhance enzyme function and create novel semisynthetic biocatalysts, as well as provide a perspective in a fast-evolving topic.
Open AccessProtein Modifications: From Chemoselective Probes to Novel Biocatalysts
Chemical reactions can be performed to covalently modify specific residues in proteins. When applied to native enzymes, these chemical modifications can greatly expand the available set of building blocks for the development of biocatalysts. Nucleophilic canonical amino acid sidechains are the most readily accessible targets for such endeavors. A rich history of attempts to design enhanced or novel enzymes, from various protein scaffolds, has paved the way for a rapidly developing field with growing scientific, industrial, and biomedical applications. A major challenge is to devise reactions that are compatible with native proteins and can selectively modify specific residues. Cysteine, lysine, N-terminus, and carboxylate residues comprise the most widespread naturally occurring targets for enzyme modifications. In this review, chemical methods for selective modification of enzymes will be discussed, alongside with examples of reported applications. We aim to highlight the potential of such strategies to enhance enzyme function and create novel semisynthetic biocatalysts, as well as provide a perspective in a fast-evolving topic.
- Open Access
- 21 October 2020
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 8, 586942
Unveiling Druggable Pockets by Site-Specific Protein Modification: Beyond Antibody-Drug Conjugates
Site-specific modification approaches have been extensively employed in the development of protein-based technologies. In this field, stability and activity integrity are the envisioned features of chemically modified proteins. These methods are especially used in the design of antibody-drug conjugates (ADCs). Nevertheless, a biochemical feature of the target protein in these reactions is often overlooked, residue specificity. Usually, in the course of developing chemical probes to modify a protein of interest (POI), specific amino acids are selected due to their reactivity. It is not critical which residue is modified as long as its modification does not compromise the POI's activity. However, no attention is paid as to why certain residues are preferentially modified over others. Physicochemical and structural constraints are often involved in the reactivity of the residue and account for the preferential modification. We propose that site-specific protein modification approaches can be applied beyond the development of ADCs or protein-drug conjugates, and used as a tool to reveal functionally relevant residues. By preferentially modifying certain side chains in the POI, chemical probes can uncover new binding motifs to investigate. Here we describe methods for protein modification, and how some pitfalls in the field can be turned into tools to reveal and exploit druggable pockets. Thus, allowing the design of innovative inhibitors against disease-relevant POIs. We discuss methodologies for site-specific modification of lysine, tryptophan, cysteine, histidine and tyrosine and comment on instances where the modified residues were used as targets for functionalization or drug design.
- 21 October 2020
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 8, 586942
Open AccessUnveiling Druggable Pockets by Site-Specific Protein Modification: Beyond Antibody-Drug Conjugates
Site-specific modification approaches have been extensively employed in the development of protein-based technologies. In this field, stability and activity integrity are the envisioned features of chemically modified proteins. These methods are especially used in the design of antibody-drug conjugates (ADCs). Nevertheless, a biochemical feature of the target protein in these reactions is often overlooked, residue specificity. Usually, in the course of developing chemical probes to modify a protein of interest (POI), specific amino acids are selected due to their reactivity. It is not critical which residue is modified as long as its modification does not compromise the POI's activity. However, no attention is paid as to why certain residues are preferentially modified over others. Physicochemical and structural constraints are often involved in the reactivity of the residue and account for the preferential modification. We propose that site-specific protein modification approaches can be applied beyond the development of ADCs or protein-drug conjugates, and used as a tool to reveal functionally relevant residues. By preferentially modifying certain side chains in the POI, chemical probes can uncover new binding motifs to investigate. Here we describe methods for protein modification, and how some pitfalls in the field can be turned into tools to reveal and exploit druggable pockets. Thus, allowing the design of innovative inhibitors against disease-relevant POIs. We discuss methodologies for site-specific modification of lysine, tryptophan, cysteine, histidine and tyrosine and comment on instances where the modified residues were used as targets for functionalization or drug design.
- Open Access
- 19 July 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (8) , 1417-1424
Enhancement of the Anti-Aggregation Activity of a Molecular Chaperone Using a Rationally Designed Post-Translational Modification
Protein behavior is closely regulated by a plethora of post-translational modifications (PTMs). It is therefore desirable to develop approaches to design rational PTMs to modulate specific protein functions. Here, we report one such method, and we illustrate its successful implementation by potentiating the anti-aggregation activity of a molecular chaperone. Molecular chaperones are a multifaceted class of proteins essential to protein homeostasis, and one of their major functions is to combat protein misfolding and aggregation, a phenomenon linked to a number of human disorders. In this work, we conjugated a small-molecule inhibitor of the aggregation of α-synuclein, a process associated with Parkinson’s disease (PD), to a specific cysteine residue on human Hsp70, a molecular chaperone with five free cysteines. We show that this regioselective conjugation augments in vitro the anti-aggregation activity of Hsp70 in a synergistic manner. This Hsp70 variant also displays in vivo an enhanced suppression of α-synuclein aggregation and its associated toxicity in a Caenorhabditis elegans model of PD.
- 19 July 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (8) , 1417-1424
Open AccessEnhancement of the Anti-Aggregation Activity of a Molecular Chaperone Using a Rationally Designed Post-Translational Modification
Protein behavior is closely regulated by a plethora of post-translational modifications (PTMs). It is therefore desirable to develop approaches to design rational PTMs to modulate specific protein functions. Here, we report one such method, and we illustrate its successful implementation by potentiating the anti-aggregation activity of a molecular chaperone. Molecular chaperones are a multifaceted class of proteins essential to protein homeostasis, and one of their major functions is to combat protein misfolding and aggregation, a phenomenon linked to a number of human disorders. In this work, we conjugated a small-molecule inhibitor of the aggregation of α-synuclein, a process associated with Parkinson’s disease (PD), to a specific cysteine residue on human Hsp70, a molecular chaperone with five free cysteines. We show that this regioselective conjugation augments in vitro the anti-aggregation activity of Hsp70 in a synergistic manner. This Hsp70 variant also displays in vivo an enhanced suppression of α-synuclein aggregation and its associated toxicity in a Caenorhabditis elegans model of PD.
- 3 October 2018
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 57 (43) , 6144-6152
Posttranslational Chemical Mutagenesis: To Reveal the Role of Noncatalytic Cysteine Residues in Pathogenic Bacterial Phosphatases
The field of chemical site-selective modification of proteins has progressed extensively in recent decades to enable protein functionaliza-tion for imaging, drug-delivery and functional studies. In this perspective, we provide a detailed insight into an alternative use of site-selective protein chemistry to probe the role(s) of unpaired Cys residues in the structure and function of disease relevant proteins. Phos-phatases are important players in the successful infection of pathogenic bacteria, which represent a significant health burden, particularly in multi-drug-resistant strains. Therefore, a strategy to readily probe key amino-acid role(s) in the structure and function may facilitate the targeting and inhibition of these virulence factors. With a dehydroalanine-based posttranslational chemical mutagenesis approach, it is possible to reveal hitherto unknown function(s) of non-catalytic Cys residues and confirm their role and interplay in pathogenic bacterial phosphatases. By selectively modifying reactive sulfhydryl side chains in different protein local environments, this posttranslational site-selective chemical mutagenesis approach reveals structural information about binding pockets and regulatory roles of the modified resi-dues, which can be further validated by conventional site-directed mutagenesis. Ultimately, these new binding pockets can serve as tem-plates for enhanced structure-based drug-design platforms and aid the development of potent and specific inhibitors.
- 3 October 2018
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 57 (43) , 6144-6152
Posttranslational Chemical Mutagenesis: To Reveal the Role of Noncatalytic Cysteine Residues in Pathogenic Bacterial Phosphatases
The field of chemical site-selective modification of proteins has progressed extensively in recent decades to enable protein functionaliza-tion for imaging, drug-delivery and functional studies. In this perspective, we provide a detailed insight into an alternative use of site-selective protein chemistry to probe the role(s) of unpaired Cys residues in the structure and function of disease relevant proteins. Phos-phatases are important players in the successful infection of pathogenic bacteria, which represent a significant health burden, particularly in multi-drug-resistant strains. Therefore, a strategy to readily probe key amino-acid role(s) in the structure and function may facilitate the targeting and inhibition of these virulence factors. With a dehydroalanine-based posttranslational chemical mutagenesis approach, it is possible to reveal hitherto unknown function(s) of non-catalytic Cys residues and confirm their role and interplay in pathogenic bacterial phosphatases. By selectively modifying reactive sulfhydryl side chains in different protein local environments, this posttranslational site-selective chemical mutagenesis approach reveals structural information about binding pockets and regulatory roles of the modified resi-dues, which can be further validated by conventional site-directed mutagenesis. Ultimately, these new binding pockets can serve as tem-plates for enhanced structure-based drug-design platforms and aid the development of potent and specific inhibitors.
- Open Access
- 12 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (8) , 1948-1957
S-Nitrosylation of cIAP1 Switches Cancer Cell Fate from TNFα/TNFR1-Mediated Cell Survival to Cell Death
TNFα is a prominent proinflammatory cytokine and a critical mediator for the development of many types of cancer such as breast, colon, prostate, cervical, skin, liver, and chronic lymphocytic leukemia. Binding of TNFα to TNFR1 can lead to divergent signaling pathways promoting predominantly NF-κB activation but also cell death. We report here that the nitric oxide (NO) donor glyceryl trinitrate (GTN) converts TNFα, generated from immune cells or cancer cells stimulated by chemotherapy, into a prodeath mediator in colon and mammary cancer cells. GTN-mediated S-nitrosylation of cIAP1 on cysteines 571 and 574 inhibited its E3 ubiquitin ligase activity, which in turn reduced Lys63-linked ubiquitination of RIP1 and initiated assembly of a death complex. These findings provide insights into how NO can harness advantageous aspects of inflammation in cancer and provide new therapeutic strategies. Significance: Combination of an NO donor with chemotherapeutic drug–induced TNFα represents a potentially valuable anticancer strategy. Cancer Res; 78(8); 1948–57. ©2018 AACR.
- 12 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (8) , 1948-1957
Open AccessS-Nitrosylation of cIAP1 Switches Cancer Cell Fate from TNFα/TNFR1-Mediated Cell Survival to Cell Death
TNFα is a prominent proinflammatory cytokine and a critical mediator for the development of many types of cancer such as breast, colon, prostate, cervical, skin, liver, and chronic lymphocytic leukemia. Binding of TNFα to TNFR1 can lead to divergent signaling pathways promoting predominantly NF-κB activation but also cell death. We report here that the nitric oxide (NO) donor glyceryl trinitrate (GTN) converts TNFα, generated from immune cells or cancer cells stimulated by chemotherapy, into a prodeath mediator in colon and mammary cancer cells. GTN-mediated S-nitrosylation of cIAP1 on cysteines 571 and 574 inhibited its E3 ubiquitin ligase activity, which in turn reduced Lys63-linked ubiquitination of RIP1 and initiated assembly of a death complex. These findings provide insights into how NO can harness advantageous aspects of inflammation in cancer and provide new therapeutic strategies. Significance: Combination of an NO donor with chemotherapeutic drug–induced TNFα represents a potentially valuable anticancer strategy. Cancer Res; 78(8); 1948–57. ©2018 AACR.
- Top Cited PapersOpen Access
- 23 February 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (11) , 4004-4017
Chemo- and Regioselective Lysine Modification on Native Proteins
Site-selective chemical conjugation of synthetic molecules to proteins expands their functional and therapeutic capacity. Current protein modification methods, based on both synthetic and biochemical technologies, can achieve site-selectivity, but these techniques often require extensive sequence engineering or are restricted to the N- or C-terminus. Here we show the computer-assisted design of sulfonyl acrylate reagents for the modification of a single lysine residue on native protein sequences. This feature of the designed sulfonyl acrylates, together with the innate and subtle reactivity differences conferred by the unique local microenvironment surrounding each lysine, contribute to the observed regioselectivity of the reaction. Moreover, this site-selectivity was predicted computationally, where the lysine with the lowest pKa was the kinetically favoured residue at slightly basic pH. Chemoselectivity was also observed as the reagent reacted preferentially at lysine, even in those cases when other nucleophilic residues such as cysteine were present. The reaction is fast and proceeds using a single molar equivalent of the sulfonyl acrylate reagent under biocompatible conditions (37 ºC and pH 8.0). This technology was demonstrated by the quantitative and irreversible modification of five different proteins including the clinically used therapeutic antibody Trastuzumab without prior sequence engineering. Importantly, their natural secondary structure and functionality is retained after the modification. This regioselective lysine modification method allows for further bioconjugation through aza-Michael addition to the acrylate electrophile that is generated by spontaneous elimination of methanesulfinic acid upon lysine labelling. We showed that a protein and an antibody conjugate bearing a site-specifically installed fluorophore at lysine could be used for selective imaging of apoptotic cells and detection of Her2+ cells, respectively. This simple and robust method does not require genetic engineering and may be generally used for accessing diverse, well-defined protein conjugates for basic biology and therapeutic studies.
- 23 February 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (11) , 4004-4017
Top Cited PapersOpen AccessChemo- and Regioselective Lysine Modification on Native Proteins
Site-selective chemical conjugation of synthetic molecules to proteins expands their functional and therapeutic capacity. Current protein modification methods, based on both synthetic and biochemical technologies, can achieve site-selectivity, but these techniques often require extensive sequence engineering or are restricted to the N- or C-terminus. Here we show the computer-assisted design of sulfonyl acrylate reagents for the modification of a single lysine residue on native protein sequences. This feature of the designed sulfonyl acrylates, together with the innate and subtle reactivity differences conferred by the unique local microenvironment surrounding each lysine, contribute to the observed regioselectivity of the reaction. Moreover, this site-selectivity was predicted computationally, where the lysine with the lowest pKa was the kinetically favoured residue at slightly basic pH. Chemoselectivity was also observed as the reagent reacted preferentially at lysine, even in those cases when other nucleophilic residues such as cysteine were present. The reaction is fast and proceeds using a single molar equivalent of the sulfonyl acrylate reagent under biocompatible conditions (37 ºC and pH 8.0). This technology was demonstrated by the quantitative and irreversible modification of five different proteins including the clinically used therapeutic antibody Trastuzumab without prior sequence engineering. Importantly, their natural secondary structure and functionality is retained after the modification. This regioselective lysine modification method allows for further bioconjugation through aza-Michael addition to the acrylate electrophile that is generated by spontaneous elimination of methanesulfinic acid upon lysine labelling. We showed that a protein and an antibody conjugate bearing a site-specifically installed fluorophore at lysine could be used for selective imaging of apoptotic cells and detection of Her2+ cells, respectively. This simple and robust method does not require genetic engineering and may be generally used for accessing diverse, well-defined protein conjugates for basic biology and therapeutic studies.
- Open Access
A Water-Bridged Cysteine-Cysteine Redox Regulation Mechanism in Bacterial Protein Tyrosine Phosphatases